This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Recommendation is based on pivotal data from the phase III POLARIX study
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Subscribe To Our Newsletter & Stay Updated
